Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer

被引:11
|
作者
Li, Jianqiang [1 ,2 ,3 ]
Li, Xingliang [4 ,5 ]
Wang, Wenxian [1 ,2 ,6 ]
Shao, Yang [7 ]
Zhang, Yiping [1 ,2 ,6 ]
Song, Zhengbo [1 ,2 ,6 ]
机构
[1] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou 310022, Peoples R China
[2] Univ Chinese Acad Sci, Dept Thorac Oncol Surg, Canc Hosp, Hangzhou 310022, Peoples R China
[3] Zhejiang Canc Hosp, Dept Thorac Oncol Surg, Hangzhou 310022, Peoples R China
[4] Zhejiang Rongjun Hosp, Dept Thorac Dis Diag, Jiaxing 314000, Zhejiang, Peoples R China
[5] Zhejiang Rongjun Hosp, Treatment Ctr, Jiaxing 314000, Zhejiang, Peoples R China
[6] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou 301122, Zhejiang, Peoples R China
[7] Geneseeq Technol Inc, Translat Med Res Ctr, Toronto, ON, Canada
来源
TRANSLATIONAL ONCOLOGY | 2020年 / 13卷 / 08期
基金
中国国家自然科学基金;
关键词
LIQUID BIOPSY; EGFR MUTATION; FREE DNA; CRIZOTINIB; TISSUE; NSCLC; ALK;
D O I
10.1016/j.tranon.2020.100784
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE: This study investigated the feasibility of using malignant pleural effusion (MPE) supernatant and paired cell blocks (precipitate) for gene profiling in patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS) technique. METHODS: Stage IV non-squamous NSCLC patients with MPE were eligible in this prospective study and recruited from Zhejiang Cancer Hospital between May 2014 and October 2015. MPE supernatant and paired precipitate sample gene alterations were determined with NGS containing 14 cancer-related genes. Progression free survival (PFS) was evaluated using Kaplan-Meier method and compared using log-rank test. RESULTS: A total of 102 patients were enrolled in the present study. All pleural effusions were confirmed as malignant with cytological smears. A total of 77 paired MPE supernatant and precipitate samples were acquired from the 102 patients. The results revealed that there were no statistically significant differences in the detection rate and maximum allelic fraction between supernatant and precipitate samples (P = 1.0 and P = .6). Collectively, 172 and 158 genomic alterations with 112 shared mutations were identified in supernatant and precipitate samples, respectively. Comparable PFS was found in FGFR mutation patients according to the supernatant and precipitate sample results (14.0 vs.13.9 months, P = .90). CONCLUSIONS: These results demonstrated that MPE supernatants were comparable to precipitate samples for detection of genetic alteration. However, gene mutation heterogeneity was found between these two media types.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer
    Masago, Katsuhiro
    Fujimoto, Daichi
    Fujita, Shiro
    Hata, Akito
    Kaji, Reiko
    Ohtsuka, Kyoko
    Okuda, Chiyuki
    Takeshita, Jumpei
    Katakami, Nobuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 415 - 419
  • [2] Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer
    Fjaellegaard, Katrine
    Petersen, Jesper
    Hoegholm, Asbjorn
    Clementsen, Paul Frost
    Bodtger, Uffe
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] Atezolizumab in non-squamous non-small cell lung cancer
    Akamine, Takaki
    Toyokawa, Gouji
    Tagawa, Tetsuzo
    Seto, Takashi
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3155 - S3159
  • [4] Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    LANCET, 2021, 397 (10274): : 557 - 559
  • [5] Course of minimal pleural effusions in non-small cell lung cancer
    Kavurgaci, Suna
    Kabalak, Pinar Akin
    Kizilgoz, Derya
    Yildirim, Arife
    Saymaz, Tilbe
    Turk, Ilteris
    Yilmaz, Ulku
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2023, 14 (07): : 607 - 611
  • [6] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kitamura, Kazuhiro
    Kubota, Kaoru
    Ando, Masahiro
    Takahashi, Satoshi
    Nishijima, Nobuhiko
    Sugano, Teppei
    Toyokawa, Masaru
    Miwa, Koji
    Kosaihira, Seiji
    Noro, Rintaro
    Minegishi, Yuji
    Seike, Masahiro
    Yoshimura, Akinobu
    Gemma, Akihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 457 - 461
  • [7] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Kaoru Kubota
    Masahiro Ando
    Satoshi Takahashi
    Nobuhiko Nishijima
    Teppei Sugano
    Masaru Toyokawa
    Koji Miwa
    Seiji Kosaihira
    Rintaro Noro
    Yuji Minegishi
    Masahiro Seike
    Akinobu Yoshimura
    Akihiko Gemma
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 457 - 461
  • [8] Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world
    Pan, Pengfei
    Wu, Fengjuan
    Xu, Zhiyun
    Ji, Xiang
    Qi, Qian
    Huang, Xiaomin
    Zhao, Ruyue
    Liu, Mingtao
    Jiang, Peng
    Li, Yu
    Xu, Lisheng
    THORACIC CANCER, 2021, 12 (24) : 3416 - 3425
  • [9] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
    Belalcazar, A.
    Santos, E. S.
    Gomez, J. E.
    Lopez, E.
    Raez, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] KRAS molecular profiling in non-squamous non-small cell lung cancer (NSCLC).
    Karim, Nagla Abdel
    Starnes, Sandra
    Morris, John
    Pathrose, Peter
    Perry, Ashley
    Fathallah, Hassana
    CLINICAL CANCER RESEARCH, 2014, 20